AZ compound
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-alcoholic Fatty Liver Disease (NAFLD)
Conditions
Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH)
Trial Timeline
Nov 1, 2015 → Sep 1, 2019
NCT ID
NCT02605616About AZ compound
AZ compound is a phase 2 stage product being developed by AstraZeneca for Non-alcoholic Fatty Liver Disease (NAFLD). The current trial status is terminated. This product is registered under clinical trial identifier NCT02605616. Target conditions include Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH).
What happened to similar drugs?
0 of 4 similar drugs in Non-alcoholic Fatty Liver Disease (NAFLD) were approved
Approved (0) Terminated (0) Active (4)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02605616 | Phase 2 | Terminated |
Competing Products
20 competing products in Non-alcoholic Fatty Liver Disease (NAFLD)